Sameer Amin
Internal Medicine · Downey, CANPI 1326164633
Payments from drug & device makers
Across 222 payments — averaging $1138.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$188K
- E.r. Squibb & Sons, L.L.C.$15K
- Sanofi$12K
- Boehringer Ingelheim$10K
- Novartis$7K
- Lilly USA, LLC$7K
- plus $13K from 5 others
What the payments were for
- Consulting fees$33,52313%
- Speaking & faculty fees$205,29381%
- Travel & lodging$9,5814%
- Food & beverage$4,2482%
- Education$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 168 | $188,187 |
| E.r. Squibb & Sons, L.L.C. | 10 | $14,602 |
| Sanofi | 2 | $12,399 |
| Boehringer Ingelheim | 16 | $10,227 |
| Novartis | 3 | $7,495 |
| Lilly USA, LLC | 7 | $6,756 |
| Edwards Lifesciences | 2 | $4,950 |
| Sanofi-aventis U.S. LLC | 4 | $4,469 |
| AstraZeneca | 7 | $3,501 |
| Astellas Pharma US Inc | 2 | $39 |
| Cardiva Medical, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$252,648 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 146 | $169,232 |
| EntrestoSacubitril/Valsartan | 18 | $23,931 |
| JardianceEmpagliflozin | 14 | $16,650 |
| Potassium Chloride | 19 | $2,070 |
| Metoprolol Succinate | 175 | $1,784 |
| Amiodarone Hcl | 15 | $1,091 |
| Carvedilol | 130 | $679 |
| Atorvastatin Calcium | 193 | $612 |
| Hydralazine Hcl | 47 | $524 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 40 | $294 |
| Irbesartan | 39 | $267 |
| Furosemide | 74 | $253 |
| Ranolazine ErRanolazine | 12 | $232 |
| Ezetimibe | 14 | $177 |
| Rosuvastatin Calcium | 44 | $174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $188,187 | $169,232146 claims |
| NovartisEntresto | $7,495 | $23,93118 claims |
| Boehringer IngelheimJardiance | $10,227 | $16,65014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Downey
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.